IIPLA News
Thursday, May 14, 2026

Taylor Swift Seeks to Prevent 'Swift Home' Trademark Registration in U.S.

Pop icon Taylor Swift petitions U.S. authorities to block trademark application for 'Swift Home,' citing potential brand confusion and infringement risks.

IIPLA News Deskanonymous access0 articles left this week
Taylor Swift Seeks to Prevent 'Swift Home' Trademark Registration in U.S.
Sign In To Continue

You have reached the guest article limit.

Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.

Taylor Swift has formally requested the U.S. government to deny the trademark registration of 'Swift Home.' The singer argues that the mark could cause consumer confusion with her established brand and intellectual property. This move highlights ongoing challenges celebrities face in protecting their names and tradema…
Share This Article
Ready-to-post copy includes the article link.

Taylor Swift Seeks to Prevent 'Swift Home' Trademark Registration in U.S. Taylor Swift has formally requested the U.S. government to deny the trademark registration of 'Swift Home.' The singer argues that the mark could cause consumer confusion with her established brand and intellectual prop... Read the full IIPLA article: https://iipla.org/news/taylor-swift-seeks-to-prevent-swift-home-trademark-registration-in-u-s

Related Coverage

Continue in the newsroom

Back to newsroom
PatentsUSA

Supreme Court Agrees to Review Amarin’s 'Skinny Label' Patent Dispute

The US Supreme Court has granted certiorari to hear a patent infringement case centered on the 'skinny label' strategy employed by generic drug manufacturers, involving Amarin Pharma. The case will address whether a generic drug maker can be held liable for inducing infringement when its product is labeled for non-pat…

Thursday, May 14, 2026
LitigationUSA

Supreme Court Declines to Review Purdue Pharma’s OxyContin Patent Dispute

The U.S. Supreme Court has opted not to take up Purdue Pharma’s appeal concerning patent litigation over its opioid medication OxyContin. This decision means that prior rulings against Purdue in the patent dispute remain in effect, potentially impacting the company’s control over the drug’s intellectual property right…

Thursday, May 14, 2026